Search Results

Switching antipsychotics to partial dopamine D2-agonists in individuals affected by schizophrenia: a narrative review.

• Authors : Baumann, Pierre; Bauknecht, Philipp; Kuzin, Maxim

Subjects: DRUG therapy for schizophrenia; ONLINE information services; ARIPIPRAZOLE

• Source: International Journal of Psychiatry in Clinical Practice. Nov2023, Vol. 27 Issue 4, p367-384. 18p.

Record details

Aripiprazole for the treatment of schizophrenia: Recommendations of a panel of Spanish experts on its use in clinical practice.

• Authors : Fraguas, David; Almenta Gallego, David; Arques-Egea, Sergio

Subjects: DRUG therapy for schizophrenia; CONSENSUS (Social sciences); ARIPIPRAZOLESPAIN

• Source: International Journal of Psychiatry in Clinical Practice. Mar2023, Vol. 27 Issue 1, p82-91. 10p.

Record details

Potential cinacalcet‐clozapine interaction.

• Authors : Lam, Y. W. Francis

Subjects: *DIAGNOSIS of schizophrenia; *ARIPIPRAZOLE; *DYSTONIA

• Source: Brown University Psychopharmacology Update. Jan2023, Vol. 34 Issue 1, p2-3. 2p.

Record details

Adis summary of research: Safety, tolerability and pharmacokinetics of aripiprazole 2-monthly formulation in patients with schizophrenia or bipolar I disorder.

• Authors : Blair, Hannah A.¹

Subjects: *BIPOLAR disorder; *PATIENT safety; *CONTROLLED release preparations

• Source: Drugs & Therapy Perspectives. May2024, Vol. 40 Issue 5, p190-191. 2p.

Record details

Second-generation long-acting injections anti-psychotics improve executive functions in patients with schizophrenia: a 12-month real-world study.

• Authors : Magliocco, Fabio; de Filippis, Renato; Aloi, Matteo

Subjects: DRUG therapy for schizophrenia; ANTIPSYCHOTIC agents; CHI-squared test

• Source: International Journal of Psychiatry in Clinical Practice. Jun2020, Vol. 24 Issue 2, p201-207. 7p.

Record details

Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.

• Authors : García Álvarez, Juan Carlos; González Sánchez, Luz; García Resa, Eloy

Subjects: DRUG therapy for schizophrenia; DIAGNOSIS of schizophrenia; ANTIPSYCHOTIC agents

• Source: International Journal of Psychiatry in Clinical Practice. Mar2020, Vol. 24 Issue 1, p10-17. 8p.

Record details

FDA Clears Two Schizophrenia Meds.

• Authors : Blank, Christine

Subjects: *DRUG labeling; *PHARMACEUTICAL industry; DRUG therapy for schizophreniaUNITED States. Food & Drug Administration

• Source: Formulary Watch. 5/1/2023, p1-1. 1p.

Record details

LAI antipsychotics offer little advantage for continuation of treatment.

Subjects: DISEASE relapse prevention; DRUG therapy for schizophrenia; CONTROLLED release drugs

• Source: Brown University Psychopharmacology Update. May2023, Vol. 34 Issue 5, p1-5. 5p.

Record details

FDA Accepts NDA for Longer-Acting Aripiprazole.

Subjects: DRUG therapy for schizophrenia; DRUG approval; DRUG efficacyUNITED States. Food & Drug Administration

• Source: Formulary Watch. 9/14/2022, p1-1. 1p.

Record details

Exposure–Response Modeling in Adults and Adolescents With Schizophrenia to Support the Extrapolation of Brexpiprazole Efficacy to Adolescents.

• Authors : Wang, Xiaofeng¹ ; Gopalakrishnan, Mathangi²; Rich, Benjamin^3,4

Subjects: *RESEARCH funding; *SCHIZOPHRENIA; *ANTIPSYCHOTIC agentsUNITED States. Food & Drug Administration

• Source: Journal of Clinical Pharmacology. Oct2024, Vol. 64 Issue 10, p1236-1245. 10p.

Record details